Bank Of America Corp Avrobio, Inc. Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.15 - $1.48 $32 - $41	-28 Reduced 93.33%	2 $0
Q4 2023 Feb 14, 2024	BUY	$1.22 - $1.62 $34 - $45	28 Added 1400.0%	30 $0
Q2 2023 Aug 14, 2023	SELL	$0.58 - $1.31 $480 - $1,085	-829 Reduced 99.76%	2 $0
Q1 2023 May 12, 2023	BUY	$0.76 - $1.82 $554 - $1,328	730 Added 722.77%	831 $0
Q4 2022 Feb 10, 2023	BUY	$0.64 - $0.91 $15 - $21	24 Added 31.17%	101 $0
Q3 2022 Nov 14, 2022	SELL	$0.68 - $1.11 $2,542 - $4,150	-3,739 Reduced 97.98%	77 $0
Q2 2022 Aug 12, 2022	SELL	$0.75 - $1.33 $6,564 - $11,640	-8,752 Reduced 69.64%	3,816 $3,000
Q1 2022 May 16, 2022	SELL	$1.29 - $4.04 $14,533 - $45,514	-11,266 Reduced 47.27%	12,568 $17,000
Q4 2021 Feb 08, 2022	SELL	$3.45 - $6.05 $28,158 - $49,380	-8,162 Reduced 25.51%	23,834 $92,000
Q3 2021 Nov 15, 2021	BUY	$5.53 - $9.28 $56,251 - $94,396	10,172 Added 46.61%	31,996 $179,000
Q2 2021 Sep 13, 2021	BUY	$7.84 - $12.6 $171,100 - $274,982	21,824 New	21,824 $194,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.